Editorial
|
|
|
|
|
Mediocrity prevails in the pharmaceutical industry, with a few exceptions
|
|
|
|
Marketing Authorisations
|
|
|
|
|
An excessively dangerous appetite-suppressant combination
|
|
|
|
|
|
|
|
|
|
|
|
Yet another oncological indication, but still best to avoid using this drug
|
|
|
|
|
|
|
|
|
|
A less burdensome treatment for atypical haemolytic uraemic syndrome?
|
|
|
|
|
|
|
|
|
|
More practical in some cases
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Market withdrawal is needed
|
|
|
|
|
|
|
|
|
|
The French drug regulatory agency fails to act
|
|
|
|
|
|
|
|
|
|
|
|
Explanations about treatments are helpful
|
|
|
|
|
|
|
|
|
|
|
|
And no evidence of efficacy
|
|
|
|
|
|
Reviews
|
|
|
|
|
Prednisone and radiotherapy for symptom relief
|
|
|
|
|
|
|
|
|
|
Metastatic prostate cancer progressing despite androgen suppression: two main options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|